Workshop | Bringing health-related life science and technology sectors into IMI2

Agenda

26.11.2014 · White Atrium Building · IMI Programme Office
Avenue de la Toison D’Or 56-60 · Brussels · Belgium

09:00 – 09:30  Registration & networking breakfast

IMI2 and its Strategic Research Agenda

09:30 – 9:50  Introducing IMI2
Michel Goldman, Executive Director, IMI

9:50 – 10:20  IMI’s Scientific Research Agenda (SRA)
Salah-Dine Chibout, Head Discovery Investigation Safety & TA, Novartis

10:20 – 10:50  Coffee break

IMI Strategic Governing Group (SGG) discussion #1

The promise of new technologies for IMI’s strategic research areas:
Neurodegeneration, immunology, translational safety, diabetes and metabolic disorders

10:50 – 11:20  Case studies by IMI Strategic Governing Group (SGG) representatives:

- Improving the impact of imaging solutions on drug safety evaluation
  Gunnar Schuetz, Scientist Contrast Media Research, Bayer
  SGG Translational Safety

- Imaging activities within IMIDIA: a case report from IMI1
  Jacob Hecksher-Sorensen, Team Leader, NovoNordisk
  Work package leader of the IMI diabetes project IMIDIA

- Linking clinical neuropsychiatry and quantitative neurobiology
  Hugh Marston, Head of In Vivo Pharmacology, Eli Lilly
  Project leader of future IMI project NeuroPsy

11:20 – 12:20  Discussion
Moderator: Hugh Laverty, Senior Scientific Project Manager, IMI

12:20 – 13:30  Lunch break

IMI SGG discussion #2
Harnessing the potential of data and knowledge management and exploitation:
Innovative practices and exploitation strategies

13:30 – 14:00  Case studies by IMI Strategic Governing Group (SGG) representatives:
- **Data and Knowledge Management SGG: Enabling Platforms and the RADAR project - an IMI2 Case Study**  
  Anthony Rowe, Director, Translational Informatics and External Innovation, Janssen R&D IT  
  SGG Data and Knowledge management  
  Project leader of future IMI project RADAR

- **Improve preclinical and clinical data analysis: now and tomorrow**  
  Dominique Brees, Executive Director, Novartis Institutes for Biomedical Research  
  SGG Translational Safety

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00 – 15:00</td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td></td>
<td>Moderator: Hugh Laverty, Senior Scientific Project Manager, IMI</td>
</tr>
<tr>
<td>15:00 – 15:20</td>
<td><strong>Coffee break</strong></td>
</tr>
<tr>
<td>15:20 – 15:40</td>
<td><strong>Presentation by the European Commission</strong></td>
</tr>
<tr>
<td></td>
<td>Irene Norstedt, Head of Unit, Personalised and Innovative Medicines, DG Research &amp; Innovation, European Commission</td>
</tr>
<tr>
<td>15:40 – 16:00</td>
<td><strong>Presentation by EFPIA</strong></td>
</tr>
<tr>
<td></td>
<td>Magda Chlebus, Director Science Policy, EFPIA</td>
</tr>
<tr>
<td>16:00 – 16:30</td>
<td><strong>Questions &amp; Answers</strong></td>
</tr>
<tr>
<td>16:30 – 17:00</td>
<td><strong>Action points and conclusions</strong></td>
</tr>
<tr>
<td></td>
<td>Concluding remarks</td>
</tr>
</tbody>
</table>